4Vote!
Medical News Today (Free subscription) | 13 hours ago
Merck & Co., Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has recommended approval of ELONVA® (corifollitropin alfa injection) as a treatment in controlled ovarian stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (ART)...
3Vote!
Law Blog - WSJ.com (Free subscription) | 22 hours ago
A bigger-than-expected drop in Dell's earnings and a pullback for global industrials, including Caterpillar, pushed stocks lower Friday, though continued strength for some defensive blue chips like Merck kept the Dow industrials in the black for the week.
+Vote!
SeekingAlpha.com (Free subscription) | 22 hours ago
The Burrill Report submits: A small study is causing a big splash in the multi-billion dollar world of cholesterol treatments. The test, pitting a prescription form of the B vitamin niacin against the prescription drug ezetimibe, found that niacin significantly shrank artery walls when taken in combination with a statin. The commercial version of ezetimibe by contrast, sold by Merck ( MRK ) as Zetia,...
3Vote!
Contract Pharma Breaking News (Free subscription) | yesterday
Ligand Pharmaceuticals, Inc. has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck , through its research collaboration, which is due to expire at the end of December. “We have had a long and productive drug discovery relationship with Organon and Schering-Plough (which acquired Organon in November 2007) over the years for a range of research programs,”...
3Vote!
Seattle Times (Free subscription) | yesterday
Drug developer Merck & Co. said Friday a European advisory committee recommended approval for the company's fertility drug Elonva.
3Vote!
Seattle Post-Intelligencer (Free subscription) | yesterday
WHITEHOUSE STATION, N.J. -- Drug developer Merck & Co. said Friday a European advisory committee recommended approval for the company's fertility drug Elonva.
3Vote!
In the Pipeline (Free subscription) | yesterday
So, according to this report , Merck is scouting out locations for a UK facility. No word if it's supposed to have a research component, but. . .as a correspondent points out, if only there were a large research campus that they could somehow get their hands on, convenient to both Cambridge and London, with all the facilities they might need. . .hmmm. . .
3Vote!
Red Orbit (Free subscription) | yesterday
WHITEHOUSE STATION, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Merck & Co., Inc.
3Vote!
Market Watch (Free subscription) | yesterday
MADRID (MarketWatch) -- German pharmaceutical and chemical company Merck KGaA was downgraded to hold from buy on Friday at Citigroup, which said the risk-reward looks evenly balanced. The rejection of Erbitux by the Committee for Medicinal Products for Human Use on appeal in non-small lung cancer is a negative, said the analysts who are removing potential related sales from their forecast model. That's...
3Vote!
San Fransisco Chronicle (Free subscription) | 19/11/2009
Ligand Pharmaceuticals Inc. said Thursday it received a $2 million milestone payment from Merck & Co. as part of a research collaboration. The company said the partnership covers a range of research programs. It is due to expire at the end of December. Ligand... Merck & Co - Business - Pharmaceutical - Biotechnology and Pharmaceuticals - Schering-Plough
3Vote!
Daily News Analysis (Free subscription) | 19/11/2009
Amid cancer, diabetes, strokes, flu, arthritis, etc, this life threatening disease, which affects millions of poor people in the world, finds negligible public attention or favour with drugmakers.
3Vote!
Xconomy (Free subscription) | 19/11/2009
San Diego-based Ligand Pharmaceuticals (NASDAQ: LGND) said today it has received $2 million in milestone payments as part of research collaboration with Merck that is due to expire next month. The partnership started with Organon, which was later acquired by Schering-Plough, which was then acquired by Merck.
3Vote!
PR News Wire (Free subscription) | 19/11/2009
CHICAGO, Nov. 19 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for MRK, MON, URBN, HK, and VPRT.
Explore : Apparel Stores,
Business Services,
Chemicals,
Drug Manufacturers,
Electronic Commerce,
Financial Services,
Health Industries,
Monsanto,
Price comparison,
Pricewatch,
Print and Communication Services,
Urban Outfitters,
VistaPrint